Evidence map›Paper›PMID 37520555›Full record

ArticleFrontiers in immunology2023

Antigen-specific cytokine profiles for pulmonary

Yoshiro Yamashita, Ikkoh Yasuda, Takeshi Tanaka, Toru Ikeda, Mayumi Terada, Masahiro Takaki, Yoshiko Tsuchihashi, Norichika Asoh, Yukiko Ohara, Shymaa Enany and 3 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Yoshiro YamashitaDepartment of Clinical Medicine, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Nagasaki, Japan.
Ikkoh YasudaDepartment of Clinical Medicine, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Nagasaki, Japan.
Takeshi TanakaInfection Control and Education Center, Nagasaki University Hospital, Nagasaki, Nagasaki, Japan.
Toru IkedaDepartment of Respiratory Medicine, Nagasaki Rosai Hospital, Sasebo, Nagasaki, Japan.
Mayumi TeradaDepartment of Internal Medicine, Koseikai Nijigaoka Hospital, Nagasaki, Nagasaki, Japan.
Masahiro TakakiDepartment of Respiratory Medicine, Shunkaikai Inoue Hospital, Nagasaki, Nagasaki, Japan.
Yoshiko TsuchihashiDepartment of Respiratory Medicine, Juzenkai Hospital, Nagasaki, Nagasaki, Japan.
Norichika AsohDepartment of Respiratory Medicine, Juzenkai Hospital, Nagasaki, Nagasaki, Japan.
Yukiko OharaDepartment of Bacteriology, Niigata University Graduate School of Medicine, Niigata, Niigata, Japan.
Shymaa EnanyDepartment of Microbiology and Immunology, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt.
Haruka KobayashiDepartment of Bacteriology, Niigata University Graduate School of Medicine, Niigata, Niigata, Japan.
Sohkichi MatsumotoDepartment of Bacteriology, Niigata University Graduate School of Medicine, Niigata, Niigata, Japan.
Konosuke MorimotoDepartment of Internal Medicine, Koseikai Nijigaoka Hospital, Nagasaki, Nagasaki, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Controlling pulmonary Methods: A total of 47 MAC patients at different stages based on clinical information (14 before-treatment, 16 on-treatment, and 17 after-treatment) and 17 healthy controls were recruited. Peripheral blood mononuclear cells were cultured with specific antigens (MAV0968, 1160, 1276, and 4925), and the cytokine profiles (IFN-γ, TNF-α, IL-2, IL-10, IL-13, and IL-17) of CD4+/CD3+ and CD19+ cells were analyzed by flow cytometry. Results: The response of Th1 cytokines such as IFN-γ and TNF-α against various antigens was significantly higher in both the on-treatment and after-treatment groups than in the before-treatment group and control (P < 0.01-0.0001 and P < 0.05-0.0001). An analysis of polyfunctional T cells suggested that the presence of IL-2 is closely related to the stage after the start of treatment (P = 0.0309-P < 0.0001) and is involved in memory function. Non-Th1 cytokines, such as IL-10 and IL-17, showed significantly higher responses in the before-treatment group (P < 0.0001 and P < 0.01-0.0001). These responses were not observed with purified protein derivative (PPD). CD19+B cells showed a response similar to that of CD4+T cells. Conclusion: There is a characteristic cytokine profile at each clinical stage of MAC.

Indexed as

Lung DiseasesMycobacterium avium-intracellulare InfectionCytokinesHumansInterleukin-10Interleukin-17Interleukin-2Leukocytes, MononuclearMycobacterium avium ComplexTumor Necrosis Factor-alphaCytokinesInterleukin-10Interleukin-17Interleukin-2Tumor Necrosis Factor-alphaCD19+B cellsCD4+T cellscell-mediated immunityclinical stagecytokine profileMycobacterium avium-associated antigensMycobacterium avium complex disease

Identifiers

PMID37520555
PMCPMC10380938

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.